比美吉珠单抗治疗活动性中轴型脊柱关节炎患者:随机平行III期BE MOBILE 1和BE MOBILE 2研究52周疗效与安全性
BE MOBILE 1(非放射学中轴型脊柱关节炎)和BE MOBILE 2(放射学中轴型脊柱关节炎)两项III期研究显示,比美吉珠单抗(BKZ)双靶抑制IL-17A和IL-17F,第16周相比安慰剂的疗效改善维持至第52周;第52周安全性与已知安全性一致。
要点
- 第16周BKZ较安慰剂的疗效改善(ASAS40、ASDAS、hsCRP、MRI炎症)维持至第52周
- 第16周由安慰剂转换为BKZ的患者第52周应答与BKZ随机组相当
- 第52周最常见真菌感染为口腔念珠菌病(nr-axSpA 7.4%;r-axSpA 6.1%)
核心结论
- 第52周时,BKZ双靶抑制IL-17A和IL-17F在全部中轴型脊柱关节炎谱系中产生持续疗效,安全性特征与BKZ已知安全性一致。
研究设计与样本
- BE MOBILE 1(nr-axSpA;NCT03928704)和BE MOBILE 2(r-axSpA;NCT03928743)为随机平行III期研究,包含16周双盲安慰剂对照期和随后36周维持期。
- 自第16周起,所有患者接受皮下BKZ 160 mg每4周一次。
主要发现
- 第16周BKZ随机组较安慰剂在ASAS40应答(主要终点)、ASDAS、hsCRP水平和骶髂关节/脊柱MRI炎症方面的改善维持至第52周。
- 第52周时,第16周由安慰剂转换为BKZ的患者应答与BKZ随机组患者相当。
- 第52周时,nr-axSpA和r-axSpA患者中分别有183例(75.0%)和249例(75.5%)报告至少1例治疗中出现的不良事件(TEAE)。
- 严重TEAE在nr-axSpA患者中发生9例(3.7%),在r-axSpA患者中发生20例(6.1%)。
- 口腔念珠菌病是最常见的真菌感染(nr-axSpA:18例(7.4%);r-axSpA:20例(6.1%))。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) at Week 16. Here, the objective is to report the efficacy and safety of BKZ at Week 52. METHODS: BE MOBILE 1 (nr-axSpA; NCT03928704) and BE MOBILE 2 (r-axSpA; NCT03928743) comprised a 16-week, double-blind, placebo-controlled period, then a 36-week maintenance period. From Week 16, all patients received subcutaneous BKZ 160 mg every 4 weeks. RESULTS: Improvements versus placebo in Assessment of SpondyloArthritis International Society ≥40% response (primary endpoint), Ankylosing Spondylitis Disease Activity Score, high-sensitivity C-reactive protein levels and MRI inflammation of the sacroiliac joints/spine at Week 16 were sustained to Week 52 in BKZ-randomised patients. At Week 52, responses of patients switching from placebo to BKZ at Week 16 were comparable to BKZ-randomised patients. At Week 52, ≥1 treatment-emergent adverse events (TEAEs) were reported in 183 (75.0%) and 249 (75.5%) patients with nr-axSpA and r-axSpA, respectively. Serious TEAEs occurred in 9 (3.7%) patients with nr-axSpA and 20 (6.1%) patients with r-axSpA. Oral candidiasis was the most frequent fungal infection (nr-axSpA: 18 (7.4%); r-axSpA: 20 (6.1%)). Uveitis occurred in three (1.2%) and seven (2.1%) patients with nr-axSpA and r-axSpA, and inflammatory bowel disease in two (0.8%) and three (0.9%). CONCLUSIONS: At Week 52, dual inhibition of IL-17A and IL-17F with BKZ resulted in sustained efficacy across the axSpA spectrum; the safety profile was consistent with the known safety of BKZ. TRIAL REGISTRATION NUMBER: NCT03928704; NCT03928743.
引用
- Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024. PMID: 37793792. doi:10.1136/ard-2023-224803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。